Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$270.56
$257.98
$186.05
▼
$282.15
$16.88B0.35534,748 shs723,460 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$74.84
$80.80
$48.78
▼
$93.42
$14.63B0.972.04 million shs1.54 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
$55.16
$33.76
▼
$59.72
$14.62B0.422.16 million shs1.58 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$19.04
$19.34
$3.86
▼
$21.27
$4.17B1.692.36 million shs2.05 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+9.14%+5.93%+31.46%+31.40%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-2.30%-11.41%+11.09%+40.20%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.37%+9.14%+14.05%+55.78%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
0.00%+1.44%-3.69%+39.39%+362.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$270.56
$257.98
$186.05
▼
$282.15
$16.88B0.35534,748 shs723,460 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$74.84
$80.80
$48.78
▼
$93.42
$14.63B0.972.04 million shs1.54 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$59.01
$55.16
$33.76
▼
$59.72
$14.62B0.422.16 million shs1.58 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$19.04
$19.34
$3.86
▼
$21.27
$4.17B1.692.36 million shs2.05 million shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%+9.14%+5.93%+31.46%+31.40%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-2.30%-11.41%+11.09%+40.20%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+8.37%+9.14%+14.05%+55.78%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
0.00%+1.44%-3.69%+39.39%+362.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$310.0514.60% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$101.5335.66% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.35
Hold$50.07-15.16% Downside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.93
Moderate Buy$25.9236.12% Upside

Current Analyst Ratings Breakdown

Latest RLAY, ASND, BBIO, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$304.00 ➝ $312.00
9/1/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$96.00 ➝ $110.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$275.00 ➝ $273.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$327.00
9/1/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$333.00 ➝ $330.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$328.00 ➝ $326.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$345.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$306.00 ➝ $304.00
(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M20.72N/AN/A($2.97) per share-91.10
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M29.14N/AN/A($10.77) per share-6.95
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B6.30$3.03 per share19.49$8.06 per share7.32
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$15.35M271.82N/AN/A$3.27 per share5.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8920.9930.40N/A70.99%32.54%7.71%11/11/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1818.5615.861.7635.33%42.17%31.76%11/3/2026 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$276.48M-$1.57N/AN/AN/AN/A-42.27%-38.67%11/5/2026 (Estimated)

Latest RLAY, ASND, BBIO, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.3911-$0.41-$0.0189-$0.41$0.96 million$0.35 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
18.27
18.27

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
5.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330219.14 million208.10 millionOptionable

Recent News About These Companies

Frazier Life Sciences Management L.P. Takes $19 Million Position in Relay Therapeutics, Inc. $RLAY
September 7 at 4:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-frazier-life-sciences-management-lp-takes-19-million-position-in-relay-therapeutics-inc-rlay-2026-09-07/
Raiffeisen Bank International AG Cuts Stock Position in Relay Therapeutics, Inc. $RLAY
September 6 at 5:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-raiffeisen-bank-international-ag-cuts-stock-position-in-relay-therapeutics-inc-rlay-2026-09-06/
Legal & General Group Plc Acquires New Shares in Relay Therapeutics, Inc. $RLAY
September 6 at 4:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-acquires-new-shares-in-relay-therapeutics-inc-rlay-2026-09-06/
Seven Fleet Capital Management LP Has $3.33 Million Stock Position in Relay Therapeutics, Inc. $RLAY
September 5 at 4:40 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-has-333-million-stock-position-in-relay-therapeutics-inc-rlay-2026-09-05/
Bank of New York Mellon Corp Acquires New Shares in Relay Therapeutics, Inc. $RLAY
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-acquires-new-shares-in-relay-therapeutics-inc-rlay-2026-09-03/
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts
September 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000065
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-relay-therapeutics-inc-nasdaq-rlay-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-09-03/
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
September 2, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/09/02/relay-therapeutics-cfo-sells-17717-shares-for-350000/
Relay Therapeutics to Participate in Upcoming September Healthcare Conference Fireside Chats
September 1, 2026  |  quiverquant.comQ
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3354648/0/en/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-september.html
263,506 Shares in Relay Therapeutics, Inc. $RLAY Acquired by The Manufacturers Life Insurance Company
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-263506-shares-in-relay-therapeutics-inc-rlay-acquired-by-the-manufacturers-life-insurance-company-2026-09-01/
Moore Capital Management LP Purchases Shares of 414,005 Relay Therapeutics, Inc. $RLAY
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-moore-capital-management-lp-purchases-shares-of-414005-relay-therapeutics-inc-rlay-2026-08-31/
Relay Therapeutics (NASDAQ:RLAY) Major Shareholder Sells $116,400,000.00 in Stock
August 31, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30994721
Peter Rahmer Sells 4,508 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock
August 29, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rlay-insider-buying-and-selling-2026-08-29/
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 4,508 Shares of Stock
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-relay-therapeutics-nasdaq-rlay-insider-sells-4508-shares-of-stock-2026-08-28/
SoftBank Vision Fund Subsidiary Sells 6 Million Shares of Relay Therapeutics at $19.4 Each
August 28, 2026  |  kalkinemedia.comK
Relay Therapeutics (NASDAQ:RLAY) Major Shareholder Sells 6,000,000 Shares
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-relay-therapeutics-nasdaq-rlay-major-shareholder-sells-6000000-shares-2026-08-28/
J. Goldman & Co LP Takes Position in Relay Therapeutics, Inc. $RLAY
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-j-goldman-co-lp-takes-position-in-relay-therapeutics-inc-rlay-2026-08-27/
Sanctuary Advisors LLC Makes New $2 Million Investment in Relay Therapeutics, Inc. $RLAY
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sanctuary-advisors-llc-makes-new-2-million-investment-in-relay-therapeutics-inc-rlay-2026-08-27/
Deutsche Bank AG Invests $3.07 Million in Relay Therapeutics, Inc. $RLAY
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-invests-307-million-in-relay-therapeutics-inc-rlay-2026-08-27/
15,288,202 Shares in Relay Therapeutics, Inc. $RLAY Bought by BlackRock Inc.
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-15288202-shares-in-relay-therapeutics-inc-rlay-bought-by-blackrock-inc-2026-08-27/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$270.56 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$74.84 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$59.01 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$19.04 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas